Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis

被引:6
|
作者
Niu, Xiao-Wei [1 ]
Zhang, Jing-Jing [2 ]
Bai, Ming [3 ]
Peng, Yu [3 ]
Zhang, Zheng [3 ]
机构
[1] Lanzhou Univ, Clin Med Sch 1, Lanzhou, Gansu, Peoples R China
[2] Baiyin Second Peoples Hosp, Baiyin, Peoples R China
[3] Lanzhou Univ, Dept Cardiol, Hosp 1, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
关键词
Glycoprotein IIb/IIIa inhibitors; Meta-analysis; Myocardial reperfusion; Thrombectomy; Percutaneous coronary intervention; MANUAL THROMBUS ASPIRATION; PRIMARY ANGIOPLASTY; COMBINATION TREATMENT; INFARCTION; ABCIXIMAB; TIROFIBAN; PERFUSION; IMPACT; EPTIFIBATIDE; MORTALITY;
D O I
10.11909/j.issn.1671-5411.2017.10.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Suboptimal myocardial reperfusion is common in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Furthermore, it results in increased infarct size and mortality rates. We performed a meta-analysis to evaluate the role of aspiration thrombectomy (AT) combined with intracoronary administration of glycoprotein IIb/IIIa inhibitors (GPI) in the improvement of myocardial reperfusion and clinical outcomes. Methods PubMed, Embase, Web of Science, and CENTRAL databases were searched for randomized controlled trials (RCTs) investigating combined AT and intracoronary GPI treatment versus AT alone. Outcomes of interest were thrombolysis in myocardial infarction myocardial perfusion grade (TMPG), infarct size (IS) assessed by cardiac magnetic resonance imaging, left ventricular ejection fraction (LVEF), major adverse cardiac events (MACE) at short-term (<= 1 month) and long-term (6. 12 months) follow-up, and bleeding complications during the hospital stay. Results Eight trials involving 923 patients were included. Compared with AT alone, combined AT and intracoronary GPI significantly increased TMPG 3 flow (RR: 1.15, 95% CI: 1.04 to 1.26), reduced IS [mean difference (MD): -3.46, 95% CI: -5.18 to -1.73], and improved LVEF (MD: 1.44, 95% CI: 0.54 to 2.33). Furthermore, GPI use decreased the risk of MACE at long-term follow-up (RR: 0.60, 95% CI: 0.37 to 0.98). There was no significant difference between the two groups in the incidence of minor and major bleeding complications. Conclusions Our findings showed that compared with AT alone, combined AT and intracoronary GPI treatment resulted in improved myocardial reperfusion, better cardiac function, and MACE-free survival benefits at the long-term follow-up for patients with STEMI undergoing PPCI.
引用
收藏
页码:614 / 623
页数:10
相关论文
共 50 条
  • [31] Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials
    Tian, Rui
    Liu, Rugang
    Zhang, Jiajun
    Li, Yong
    Wei, Shujian
    Xu, Feng
    Li, Xiaoxing
    Li, Chuanbao
    HELIYON, 2023, 9 (05)
  • [32] Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function
    Pellicori, Pierpaolo
    Torromeo, Concetta
    Barilla, Francesco
    Mangieri, Enrico
    Evangelista, Antonietta
    Truscelli, Giovanni
    Costanzo, Pierluigi
    Hoye, Angela
    Wong, Kenneth
    CARDIOLOGY JOURNAL, 2013, 20 (03) : 310 - 317
  • [33] Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention
    Muraca, Iacopo
    Pennesi, Matteo
    Mattesini, Alessio
    Migliorini, Angela
    Carrabba, Nazario
    Virgili, Giacomo
    Bruscoli, Filippo
    Demola, Pierluigi
    Colombi, Riccardo
    Pontecorboli, Giulia
    Marchionni, Niccolo
    Di Mario, Carlo
    Valenti, Renato
    CARDIOLOGY JOURNAL, 2021,
  • [34] Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors
    Abtahian, Farhad
    Waldo, Stephen
    Jang, Ik-Kyung
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2015, 86 (03) : 390 - 396
  • [35] Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Piccolo, Raffaele
    Eitel, Ingo
    Galasso, Gennaro
    Iversen, Allan Zeeberg
    Gu, Youlan L.
    Dominguez-Rodriguez, Alberto
    de Smet, Bart J. G. L.
    Mahmoud, Karim D.
    Abreu-Gonzalez, Pedro
    Thiele, Holger
    Piscione, Federico
    VASCULAR PHARMACOLOGY, 2015, 73 : 32 - 37
  • [36] Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis
    Han, Yao-Yao
    Li, Zheng-Xiang
    Duan, Rong
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2021, 22 (01) : 167 - 174
  • [37] Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention
    Bedjaoui, Ali
    Allal, Karima
    Lounes, Mohamed Sofiane
    Belhadi, Chams Eddine
    Mekarnia, Abdelmoumen
    Sediki, Saber
    Kara, Maamar
    Azaza, Adel
    Monsuez, Jean-Jacques
    Benkhedda, Salim
    CARDIOVASCULAR JOURNAL OF AFRICA, 2019, 30 (01) : 45 - 51
  • [38] Bleeding complications associated with glycoprotein IIb/IIIa inhibitors in patients 80 years of age and older undergoing percutaneous coronary intervention
    Germing, Alfried
    Bojara, Waldemar
    Lawo, Thomas
    Ewers, Aydan
    Grewe, Peter
    Muegge, Andreas
    Lindstaedt, Michael
    EXPERIMENTAL & CLINICAL CARDIOLOGY, 2010, 15 (03) : E57 - E60
  • [39] Local Intracoronary Infusion of Glycoprotein IIb/IIIa Inhibitors via a Perfusion Catheter versus Intracoronary Guiding Catheter Injection during Primary Percutaneous Coronary Intervention: A Pilot Observational Study
    Zaki, Tarek
    Labib, Salwa
    El-Abbady, Maged
    El-Kilany, Wael
    Mortada, Ayman
    Rashid, Tarek
    Ragy, Hany
    El-ltrebyl, Adel
    Nammas, Wail
    ACTA CARDIOLOGICA SINICA, 2017, 33 (03) : 258 - 265
  • [40] Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: A review
    Truong, KM
    Amankwa, K
    Kucukarslan, S
    CLINICAL THERAPEUTICS, 2001, 23 (08) : 1145 - 1165